We are live on ! Find out more
HZNP

Horizon Therapeutics Public Limited Company Ordinary Shares

Delisted

HZNP was delisted on the 5th of October, 2023.

120 hedge funds and large institutions have $740M invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2014 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 44 increasing their positions, 39 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

688% more call options, than puts

Call options by funds: $31.3M | Put options by funds: $3.97M

13% more repeat investments, than reductions

Existing positions increased: 44 | Existing positions reduced: 39

15% less funds holding

Funds holding: 141120 (-21)

24% less capital invested

Capital invested by funds: $973M → $740M (-$233M)

29% less funds holding in top 10

Funds holding in top 10: 75 (-2)

43% less first-time investments, than exits

New positions opened: 28 | Existing positions closed: 49

Holders
120
Holders Change
-21
Holders Change %
-14.89%
% of All Funds
3.48%
Holding in Top 10
5
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-28.57%
% of All Funds
0.15%
New
28
Increased
44
Reduced
39
Closed
49
Calls
$31.3M
Puts
$3.97M
Net Calls
+$27.3M
Net Calls Change
+$4.07M

HZNP Hedge Fund Activity: Q3 2014 in Review

120 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q3 2014, worth a combined $740M — down 24% from $973M a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of HZNP and 28 opened new positions — a net loss of 21 holders — while 39 trimmed existing stakes and 44 added.

The largest buyer was Deerfield Management, adding an estimated $57M. The largest seller was Essex Woodlands Management, exiting entirely with an estimated $89M sold.

  • 120 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q3 2014, down from 141 in Q2 2014.
  • Funds reported $740M of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q3 2014, down 24% quarter-over-quarter.
  • 28 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q3 2014 and 49 closed out, a net change of -21 holders.
  • The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q3 2014 was Deerfield Management, an estimated $57M added.
  • The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q3 2014 was Essex Woodlands Management, an estimated $89M sold.

Based on aggregated 13F filings for Q3 2014.